Live Breaking News & Updates on Mutated Metastatic Melanoma

The 7-year follow-up data for encorafenib/binimetinib showing that around 21% of patients remained progression-free supports BRAF/MEK inhibition as a later treatment option after immunotherapy failure, but doctors are reluctant to stop BRAF/MEK inhibitors given lack of data, even in those patients doing well long-term on the medications with minimal toxicity. ....

Expert Perspectives , Plus Binimetinib , Mutated Metastatic Melanoma , Year Follow Up Data From , Melanoma Treatments , Braf Mutation , Targeted Therapies , Brain Metastases , Clinical Trials , Pd 1 Resistant Melanoma , Patient Population , Unmet Need , Adjuvant Therapy ,